(Q38113738)

29 August 2017

title

Detection of minimal residual disease in pediatric acute lymphoblastic leukemia (English)

1 reference

29 August 2017

1 reference

Giuseppe Gaipa

1

1 reference

29 August 2017

Giuseppe Basso

series ordinal

2

1 reference

29 August 2017

Andrea Biondi

series ordinal

3

1 reference

29 August 2017

Dario Campana

series ordinal

4

1 reference

29 August 2017

publication date

26 June 2013

1 reference

Cytometry Part B: Clinical Cytometry

29 August 2017

published in

1 reference

29 August 2017

volume

84

1 reference

29 August 2017

issue

6

1 reference

29 August 2017

page(s)

359-369

1 reference

Treatment of acute lymphoblastic leukemia

29 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Minimal residual disease in leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Determination of minimal residual disease in leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Childhood acute lymphoblastic leukaemia--current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leu

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Advances in the immunological monitoring of childhood acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

A deep profiler's guide to cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

A practical approach to multicolor flow cytometry for immunophenotyping

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Single laser three color immunofluorescence staining procedures based on energy transfer between phycoerythrin and cyanine 5.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Beyond six colors: a new era in flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

CHEMISTRY NOBEL: Getting a Charge Out of Plastics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Advances in complex multiparameter flow cytometry technology: Applications in stem cell research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

CD34+ cell subpopulations detected by 8-color flow cytometry in bone marrow and in peripheral blood stem cell collections: application for MRD detection in leukemia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Polychromatic flow cytometry identifies novel subsets of circulating cells with angiogenic potential in pediatric solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Flow cytometric identification and functional characterization of immature and mature circulating endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Quality assurance for polychromatic flow cytometry using a suite of calibration beads

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Improved compensation of the fluorochrome AmCyan using cellular controls

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Benign hematogone-rich lymphoid proliferations can be distinguished from B-lineage acute lymphoblastic leukemia by integration of morphology, immunophenotype, adhesion molecule expression, and architectural features

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Detection of minimal residual disease in acute leukemia by flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

A simplified flow cytometric assay identifies children with acute lymphoblastic leukemia who have a superior clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Treating childhood acute lymphoblastic leukemia without cranial irradiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

CD11b is a therapy resistance- and minimal residual disease-specific marker in precursor B-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Identification of novel markers for monitoring minimal residual disease in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

CD58 expression decreases as nonmalignant B cells mature in bone marrow and is frequently overexpressed in adult and pediatric precursor B-cell acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Detection of residual B precursor lymphoblastic leukemia by uniform gating flow cytometry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

New markers for minimal residual disease detection in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Overexpression of CD123 correlates with the hyperdiploid genotype in acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Quality control of flow cytometry data analysis for evaluation of minimal residual disease in bone marrow from acute leukemia patients during treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Introduction A: recent advances in cytometry instrumentation, probes, and methods--review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Analysis of immunoglobulin and T cell receptor genes. Part II: Possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Cytogenetic analysis of pediatric anaplastic large cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemi

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Clinical significance of minimal residual disease at day 15 and at the end of therapy in childhood acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Sequential monitoring of minimal residual disease in acute lymphoblastic leukemia: 7-year experience in a pediatric hematology/oncology unit.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Prognostic value of minimal residual disease quantification before allogeneic stem-cell transplantation in relapsed childhood acute lymphoblastic leukemia: the ALL-REZ BFM Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Monitoring MRD with flow cytometry: an effective method to predict relapse for ALL patients after allogeneic hematopoietic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Minimal residual disease detection in childhood acute lymphoblastic leukaemia patients at multiple time-points reveals high levels of concordance between molecular and immunophenotypic approaches.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Time point-dependent concordance of flow cytometry and real-time quantitative polymerase chain reaction for minimal residual disease detection in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Multiparameter phenotype mapping of normal and post-chemotherapy B lymphopoiesis in pediatric bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Prognostic importance of measuring early clearance of leukemic cells by flow cytometry in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Cy7PE and Cy7APC: bright new probes for immunofluorescence

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

OMIP-010: a new 10-color monoclonal antibody panel for polychromatic immunophenotyping of small hematopoietic cell samples

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Simple methods for the rapid exchange of flow cytometric data between remote centers

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Quality assurance for polychromatic flow cytometry

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Flow cytometric analysis of normal B cell differentiation: a frame of reference for the detection of minimal residual disease in precursor-B-ALL

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Multidimensional flow cytometry of marrow can differentiate leukemic from normal lymphoblasts and myeloblasts after chemotherapy and bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

BIOMED-1 concerted action report: flow cytometric immunophenotyping of precursor B-ALL with standardized triple-stainings

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

CD304 is preferentially expressed on a subset of B-lineage acute lymphoblastic leukemia and represents a novel marker for minimal residual disease detection by flow cytometry

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Heterogeneity in junctional regions of immunoglobulin kappa deleting element rearrangements in B cell leukemias: a new molecular target for detection of minimal residual disease

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Significant reduction of the hybrid BCR/ABL transcripts after induction and consolidation therapy is a powerful predictor of treatment response in adult Philadelphia-positive acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Level of minimal residual disease prior to haematopoietic stem cell transplantation predicts prognosis in paediatric patients with acute lymphoblastic leukaemia: a report of the Pre-BMT MRD Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Tandem application of flow cytometry and polymerase chain reaction for comprehensive detection of minimal residual disease in childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Analysis of minimal residual disease in childhood acute lymphoblastic leukemia: comparison between RQ-PCR analysis of Ig/TcR gene rearrangements and multicolor flow cytometric immunophenotyping

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukaemia by single-strand conformation polymorphism studies and highly resolutive PCR derived methods: implication for a general strategy of minimal residual disease detection

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Rearrangement status of the malignant cell determines type of secondary IgH rearrangement (V-replacement or V to DJ joining) in childhood B precursor acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal r

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Regenerating normal B-cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual disease

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the children's oncology group

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Use of peripheral blood instead of bone marrow to monitor residual disease in children with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCYTO.B.21101

7 January 2021

Identifiers

DOI

10.1002/CYTO.B.21101

1 reference

29 August 2017

1 reference